Please login to the form below

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II. Tyrosine kinase 2 (Tyk2) inhibitors could play major role. ... The phase II trial of tyrosine kinase 2 (Tyk2) inhibitor BMS-986165 showed a level of efficacy that was greater than other oral therapies for

Latest news

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib, an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing
Daily Brief: DDF hits £250m investment, Hard Brexit could cost UK £100bn in trade and troublesome results for Pfizer’s Ibrance

However, this difficulty didn’t seem to delay rival Novartis reporting some promising progression-free survival data for its selective cyclin-dependent kinase inhibitor Kisquali in combination with letrozole, which demonstrated
Lilly adds AurKa Pharma to oncology buying spree

The interesting twist is that AK-O1, an Aurora kinase A inhibitor, was originally discovered by Lilly, but offloaded in 2016 as part of a pipeline review.
Rigel and Ultragenyx claim approvals for rare drugs

All’s well that ends well however, with the US regulator giving its blessing to the first-in-class oral spleen tyrosine kinase (SYK) inhibitor after a lengthy and often turbulent
Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

The EMA and FDA have started the clock ticking on their appraisals for dacomitinib, a pan-EGFR tyrosine kinase inhibitor, for the first-line treatment of patients with locally advanced or ... September. The study showed that dacomitinib improved median

More from news
Approximately 1 fully matching, plus 164 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is
Accelerating innovation

While the company waits to hear from the EMA, there is also work underway to explore the use of Ipsen’s tyrosine-kinase inhibitor (TKI) Cabometyx in combination with some of
Deal Watch September 2016

No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective
Deal Watch June 2016

acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.
Deal Watch May 2016

Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... 282. Carna Biosciences/ ProNAi Therapeutics. Licence. $0.9m

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

Akinion appoints Dr Richard Jones as CEO

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
Creabilis names Catherine Moukheibir as chairman of the board

Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Systematic Review Lead- London: Negotiable

Senior Medical Writer: Salary is DOE

Associate Scientific Director: Salary TBC

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director or Senior Account Director: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Medical Writer - Creative and Scientific Projects: DOE

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Director, Healthcare Advertising Agency: Salary TBC

Account Manager: Negotiable

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Healthcare PR Senior Account Manager: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Solaris Health looks at the gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...